HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance

详细信息    查看全文

• 作者：Shih-Chiang Huang ; Kwai-Fong Ng ; Shang-En Lee ; Kuang-Hua Chen ; Ta-Sen Yeh…
• 关键词：Gastric cancer ; HER2 ; Biopsy ; Excision ; Discordance
• 刊名：Gastric Cancer
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：19
• 期：1
• 页码：176-182
• 全文大小：4,373 KB
• 参考文献：1.Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362:305–15.PubMed CrossRef
  2.Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.PubMed CrossRef
  3.Power DG, Kelsen DP, Shah MA. Advanced gastric cancer—slow but steady progress. Cancer Treat Rev. 2010;36:384–92.PubMed CrossRef
  4.Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2009;71:127–64.PubMed CrossRef
  5.Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.PubMed CrossRef
  6.Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–9.PubMed CrossRef
  7.Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18:53–9.PubMed CrossRef
  8.Jorgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer—a systematic analysis of data from the literature. J Cancer. 2012;3:137–44.PubMed PubMedCentral CrossRef
  9.Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.PubMed CrossRef
  10.Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805.PubMed CrossRef
  11.Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. 2011;59:832–40.PubMed CrossRef
  12.Grillo F, Fassan M, Ceccaroli C, Giacometti C, Curto M, Zagonel V, et al. The reliability of endoscopic biopsies in assessing HER2 status in gastric and gastroesophageal junction cancer: a study comparing biopsies with surgical samples. Transl Oncol. 2013;6:10–6.PubMed PubMedCentral CrossRef
  13.Pirrelli M, Caruso ML, Di Maggio M, Armentano R, Valentini AM. Are biopsy specimens predictive of HER2 status in gastric cancer patients? Dig Dis Sci. 2013;58:397–404.PubMed
  14.Watson S, Validire P, Cervera P, Zorkani N, Scriva A, Lemay F, et al. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. Ann Oncol. 2013;24:3035–9.PubMed CrossRef
  15.Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed
  16.Chang HC, Huang SC, Chen JS, Tang R, Changchien CR, Chiang JM, et al. Risk factors for lymph node metastasis in pT1 and pT2 rectal cancer: a single-institute experience in 943 patients and literature review. Ann Surg Oncol. 2012;19:2477–84.PubMed CrossRef
  17.Ruschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, et al. HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299–307.
  18.Hsu JT, Chen TC, Tseng JH, Chiu CT, Liu KH, Yeh CN, et al. Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. Oncologist. 2011;16:1706–13.PubMed PubMedCentral CrossRef
  19.Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol. 2011;18:2833–40.PubMed CrossRef
  20.Warneke VS, Behrens HM, Boger C, Becker T, Lordick F, Ebert MP, et al. HER2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol. 2013;24:725–33.PubMed PubMedCentral CrossRef
  21.Wang T, Hsieh ET, Henry P, Hanna W, Streutker CJ, Grin A. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status. Hum Pathol. 2014;45:970–5.PubMed CrossRef
  22.Yoshida H, Yamamoto N, Taniguchi H, Oda I, Katai H, Kushima R, et al. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Arch. 2014;465:145–54.PubMed CrossRef
  23.Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther. 2005;85:257–68.PubMed
  24.Kondo Y, Iijima T, Noguchi M. Evaluation of immunohistochemical staining using whole-slide imaging for HER2 scoring of breast cancer in comparison with real glass slides. Pathol Int. 2012;62:592–9.PubMed CrossRef
  25.Kim MA, Lee HJ, Yang HK, Bang YJ, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011;59:822–31.PubMed PubMedCentral CrossRef
  26.Cho EY, Park K, Do I, Cho J, Kim J, Lee J, et al. Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. Mod Pathol. 2013;26:677–84.PubMed CrossRef
  27.Fusco N, Rocco EG, Del Conte C, Pellegrini C, Bulfamante G, Di Nuovo F, et al. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Mod Pathol. 2013;26:816–24.PubMed CrossRef
  28.Liang JW, Zhang JJ, Zhang T, Zheng ZC. Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. Tumour Biol. 2014;35:4849–58.PubMed CrossRef
  29.Krishnamurti U, Silverman JF. HER2 in breast cancer: a review and update. Adv Anat Pathol. 2014;21:100–7.PubMed CrossRef
  30.Salem M, Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, et al. Association between the HER2 expression and histological differentiation in Wilms tumor. Pediatr Surg Int. 2006;22:891–6.PubMed CrossRef
  31.Sawada M, Tsuda H, Kimura M, Okamoto S, Kita T, Kasamatsu T, et al. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci. 2003;94:986–91.PubMed CrossRef
  32.Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P, et al. Erbb-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol. 2004;95:583–7.PubMed CrossRef
  33.Nuciforo PG, Pellegrini C, Fasani R, Maggioni M, Coggi G, Parafioriti A, et al. Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Hum Pathol. 2003;34:639–45.PubMed CrossRef
  34.Sato O, Wada T, Kawai A, Yamaguchi U, Makimoto A, Kokai Y, et al. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer. 2005;103:1881–90.PubMed CrossRef
  35.Borg JP, Marchetto S, Le Bivic A, Ollendorff V, Jaulin-Bastard F, Saito H, et al. ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat Cell Biol. 2000;2:407–14.PubMed CrossRef
  36.Jaulin-Bastard F, Arsanto JP, Le Bivic A, Navarro C, Vely F, Saito H, et al. Interaction between Erbin and a Catenin-related protein in epithelial cells. J Biol Chem. 2002;277:2869–75.PubMed CrossRef
  
• 作者单位：Shih-Chiang Huang (1)
  Kwai-Fong Ng (1)
  Shang-En Lee (2)
  Kuang-Hua Chen (1)
  Ta-Sen Yeh (3)
  Tse-Ching Chen (1) (4)
  
  1. Department of Anatomical Pathology, Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan, Taiwan, ROC
  2. Cancer Diagnostic Laboratory, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC
  3. Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan, Taiwan, ROC
  4. Department of Pathology, Chang Gung Memorial Hospital, No. 5 Fuxing St., Guishan Township, Taoyuan County, 333, Taiwan, ROC
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Gastroenterology
  Surgical Oncology
  Pathology
  Radiotherapy
  
• 出版者：Springer Japan
• ISSN：1436-3305

文摘

Background Inclusion of trastuzumab in chemotherapy regimens is advantageous for patients with advanced or metastatic gastric cancer who overexpress HER2. Therefore, accurate assessment of HER2 status in tumor tissue is critical when weighing treatment options.